Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Brain Tumor, Blood, Breast, Ovarian, Lung Cancer), By Technology (Cleavable, Non-cleavable Linker), And Segment Forecasts, 2019 - 2025

Published: Jan, 2019 | Pages: 110 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global antibody drug conjugate market size is expected to reach USD 9.93 billion by 2025, according to a new report by Grand View Research, Inc. it is projected to expand at a CAGR of 25.9% over the forecast period. Increasing incidence of cancer coupled with growing geriatric population are likely to drive the market for Antibody-Drug Conjugates (ADC). Furthermore, major technological advancements are also contributing to drive the growth. According to the World Health Organization (WHO), the number of people aged 65 years and above, is projected to reach 16% of the total population by 2050 from 7% in 2000. Aging has become a substantial risk factor for numerous diseases including cancer and others. Hence, the growing geriatric population is expected to drive growth of the market over the forecast period.

Until 2018, four ADCs were available in the market, namely, Adcetris, Kadcyla, Besponsa, and Mylotarg. Due to appropriate targeting and improved technology, ADCs have been gaining a lot of attention from both small and large pharmaceutical companies. Currently there are more than 50 ADCs in clinical trials and it has been projected that during the forecast period three to four ADCs will be commercialized in the area of refractory Hodgkin lymphoma, glioblastoma, small cell lung cancer, breast cancer, and ovarian cancer. It has been observed that the maximum number of clinical trials are being conducted for lymphoma.

Seattle Genetics and Roche are leading the antibody drug conjugate market in terms of market share. Until 2017 only two ADCs were commercially available-Adcetris by Seattle Genetics and Kadcyla by Roche. Recently, two more Pfizer's products were approved to be marketed for acute myeloid leukaemia and acute lymphoblastic leukaemia. Hence, it has been estimated that over the forecast period, Pfizer is anticipated to gain a significant market share.

Further key findings from the report suggest:

• Breast cancer was the largest segment in 2017 and is likely to witness a significant growth over the forecast period due to the factors such as availability of Kadcyla and high prevalence of breast cancer

• Cleavable linker is expected to witness the fastest growth over the forecast period as the maximum product in the pipeline contains cleavable linkers. In addition, in 2017 two new products-Besponsa and Mylotarg were approved in the market

• In 2017, North America was the largest revenue generating region in the antibody-drug conjugates market. It is the most well-established regions in terms of patient awareness and usage of ADCs and makes up most of the existing market

• The players operating in this space are F. Hoffmann-La Roche Ltd; Seattle Genetics, Inc.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; AbbVie Inc.; Immunomedics; and ImmunoGen Inc.

• Market players are adopting strategies, such as introducing technologically advanced products, collaborations, and geographic expansions to increase their market share. For instance, Seattle Genetics collaborated with Takeda for developing brentuximab vedotin (Adcetris) for refractory/relapsed Hodgkin lymphoma.

 Table of Contents

Chapter 1 Research Methodology & Scope
                  1.1 Information procurement
                      1.1.1 Purchased database:
                      1.1.2 GVR's internal database
                  1.2 Research methodology
                  1.3 Geographic scope & assumptions
                  1.4 Region-wise market calculation
                      1.4.1 Region-wise market: Base estimates
                      1.4.2 Global market: CAGR calculation
                  1.5 Region-based segment share calculation
                  1.6 List of secondary sources

Chapter 2 Executive Summary
                  2.1 Market snapshot

Chapter 3 Market Variables, Trends& Scope
                  3.1 Market segmentation & scope
                  3.2 Market driver analysis
                      3.2.1 Rising prevalence of cancer
                      3.2.2 Growing geriatric population base
                      3.2.3 Presence of strong product pipeline
                  3.3 Market restraint analysis
                      3.3.1 High manufacturing cost of antibody-drug conjugates 
                  3.4 Penetration & growth prospect mapping
                  3.5 Antibody-drug conjugates - SWOT analysis, by factor (political & legal, economic and technological)
                  3.6 Industry analysis - Porter's

Chapter 4 Antibody-Drug Conjugates Market: Application Outlook
                  4.1 Antibody-drug conjugates market by application, movement analysis
                  4.2 Blood cancer
                      4.2.1 Blood cancer market estimates and forecast, 2014 - 2025 (USD Million)
                      4.2.2 Leukemia
                          4.2.2.1 Leukemia market estimates and forecast, 2014 - 2025 (USD Million)
                      4.2.3 Lymphoma
                          4.2.3.1 Lymphoma market estimates and forecast, 2014 - 2025 (USD Million)
                  4.3 Breast cancer
                      4.3.1 Breast cancer market estimates and forecast, 2014 - 2025 (USD Million)
                  4.4 Ovarian cancer
                      4.4.1 Ovarian cancer market estimates and forecast, 2014 - 2025 (USD Million)
                  4.5 Lung cancer
                      4.5.1 Lung cancer market estimates and forecast, 2014 - 2025 (USD Million)
                  4.6 Brain tumor
                      4.6.1 Brain tumor market estimates and forecast, 2014 - 2025 (USD Million)

Chapter 5 Antibody-Drug Conjugates Market: Technology Outlook
                  5.1 Antibody-drug conjugates market by technology, movement analysis
                  5.2 Cleavable linker
                      5.2.1 Cleavable linker market estimates and forecast, 2014 - 2025 (USD Million)
                  5.3 Non-cleavable linker
                      5.3.1 Non-cleavable linker market estimates and forecast, 2014 - 2025 (USD Million)

Chapter 6 Antibody-Drug Conjugates Market: Regional Outlook
                  6.1 Antibody-drug conjugates market share by region, 2017 & 2025 (USD Million)
                  6.2 North America
                      6.2.1 North America antibody-drug conjugates market estimates and forecasts, 2014 - 2025 (USD Million)
                      6.2.2 U.S.
                          6.2.2.1 U.S. antibody-drug conjugates market estimates and forecasts, 2014 - 2025 (USD Million)
                      6.2.3 Canada
                          6.2.3.1 Canada antibody-drug conjugates market estimates and forecasts, 2014 - 2025 (USD Million)
                  6.3 Europe
                      6.3.1 Europe antibody-drug conjugates market estimates and forecasts, 2014 - 2025 (USD Million)
                      6.3.2 U.K.
                          6.3.2.1 U.K. antibody-drug conjugates market estimates and forecasts, 2014 - 2025 (USD Million)
                      6.3.3 Germany
                          6.3.3.1 Germany antibody-drug conjugates market estimates and forecasts, 2014 - 2025 (USD Million)
                  6.4 Asia Pacific
                      6.4.1 Asia Pacific antibody-drug conjugates market estimates and forecasts, 2014 - 2025 (USD Million)
                      6.4.2 Japan
                          6.4.2.1 Japan antibody-drug conjugates market estimates and forecasts, 2014 - 2025 (USD Million)
                      6.4.3 China
                          6.4.3.1 China antibody-drug conjugates market estimates and forecasts, 2014 - 2025 (USD Million)
                  6.5 Latin America
                      6.5.1 Latin America antibody-drug conjugates market estimates and forecasts, 2014 - 2025 (USD Million)
                      6.5.2 Brazil
                          6.5.2.1 Brazil antibody-drug conjugates market estimates and forecasts, 2014 - 2025 (USD Million)
                  6.6 MEA
                      6.6.1 MEA antibody-drug conjugates market estimates and forecasts, 2014 - 2025 (USD Million)
                      6.6.2 South Africa
                          6.6.2.1 South Africa antibody-drug conjugates market estimates and forecasts, 2014 - 2025 (USD Million)

Chapter 7 Competitive Landscape
                  7.1 Strategy framework
                  7.2 Market participation categorization
                      7.2.1 Company profiles
                      7.2.2 Seattle Genetics, Inc
                          7.2.2.1 Company overview
                          7.2.2.2 Financial performance
                          7.2.2.3 Product benchmarking
                          7.2.2.4 Strategic initiatives
                      7.2.3 Takeda Pharmaceutical Company Limited
                          7.2.3.1 Company overview
                          7.2.3.2 Financial performance
                          7.2.3.3 Product benchmarking
                          7.2.3.4 Strategic initiatives
                      7.2.4 Pfizer Inc
                          7.2.4.1 Company overview
                          7.2.4.2 Financial performance
                          7.2.4.3 Product benchmarking
                          7.2.4.4 Strategic initiatives
                      7.2.5 F. Hoffmann-La Roche Ltd
                          7.2.5.1 Company overview
                          7.2.5.2 Financial performance
                          7.2.5.3 Product benchmarking
                          7.2.5.4 Strategic initiatives
                      7.2.6 AbbVie Inc
                          7.2.6.1 Company overview
                          7.2.6.2 Financial performance
                          7.2.6.3 Product benchmarking
                          7.2.6.4 Strategic initiatives
                      7.2.7 Immunomedics
                          7.2.7.1 Company overview
                          7.2.7.2 Financial performance
                          7.2.7.3 Product benchmarking
                          7.2.7.4 Strategic initiatives
                      7.2.8 ImmunoGen Inc
                          7.2.8.1 Company overview
                          7.2.8.2 Financial performance
                          7.2.8.3 Product benchmarking
                          7.2.8.4 Strategic initiatives

List of Tables

TABLE 1 Country share estimation
TABLE 2 North America antibody-drug conjugates market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 3 North america antibody-drug conjugates market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 4 U.S. antibody-drug conjugates market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 5 U.S. antibody-drug conjugates market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 6 Canada antibody-drug conjugates market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 7 Canada antibody-drug conjugates market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 8 Europe antibody-drug conjugates market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 9 Europe antibody-drug conjugates market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 10 U.K. antibody-drug conjugates market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 11 U.K. antibody-drug conjugates market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 12 Germany antibody-drug conjugates market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 13 Germany antibody-drug conjugates market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 14 Asia Pacific antibody-drug conjugates market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 15 Asia Pacific antibody-drug conjugates market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 16 Japan antibody-drug conjugates market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 17 Japan antibody-drug conjugates market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 18 China antibody-drug conjugates market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 19 China antibody-drug conjugates market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 20 Latin America antibody-drug conjugates market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 21 Latin America antibody-drug conjugates market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 22 Brazil antibody-drug conjugates market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 23 Brazil antibody-drug conjugates market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 24 MEA antibody-drug conjugates market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 25 MEA antibody-drug conjugates market estimates and forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 26 South Africa antibody-drug conjugates market estimates and forecasts, by application, 2014 - 2025 (USD Million)
TABLE 27 South Africa antibody-drug conjugates market estimates and forecasts, by technology, 2014 - 2025 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Value chain-based sizing & forecasting
FIG. 4 QFD modeling for market share assessment
FIG. 5 Market summary
FIG. 6 Market trends &outlook
FIG. 7 Market segmentation & scope
FIG. 8 Market driver relevance analysis (Current & future impact)
FIG. 9 Market restraint relevance analysis (Current & future impact)
FIG. 10 Penetration & growth prospect mapping
FIG. 11 SWOT analysis, by factor (political & legal, economic, and technological)
FIG. 12 Porter's five forces analysis
FIG. 13 Antibody-drug conjugates market, application outlook key takeaways
FIG. 14 Antibody-drug conjugates market: application movement analysis
FIG. 15 Global blood cancer market, 2014 - 2025 (USD Million)
FIG. 16 Global leukemia market, 2014 - 2025 (USD Million)
FIG. 17 Global lymphoma market, 2014 - 2025 (USD Million)
FIG. 18 Global breast cancer market, 2014 - 2025 (USD Million)
FIG. 19 Global ovarian cancer market, 2014 - 2025 (USD Million)
FIG. 20 Global lung cancer market, 2014 - 2025 (USD Million)
FIG. 21 Global brain tumor market, 2014 - 2025 (USD Million)
FIG. 22 Antibody-drug conjugates market, technology outlook key takeaways
FIG. 23 Antibody-drug conjugates market: technology movement analysis
FIG. 24 Global clevable linker market, 2014 - 2025 (USD Million)
FIG. 25 Global non-clevable linker market, 2014 - 2025 (USD Million)
FIG. 26 Regional market place: Key takeaways
FIG. 27 Regional outlook, 2017 & 2025
FIG. 28 North America antibody-drug conjugates market, 2014 - 2025 (USD Million)
FIG. 29 U.S. antibody-drug conjugates market, 2014 - 2025 (USD Million)
FIG. 30 Canada antibody-drug conjugates market, 2014 - 2025 (USD Million)
FIG. 31 Europe antibody-drug conjugates market, 2014 - 2025 (USD Million)
FIG. 32 U.K. antibody-drug conjugates market, 2014 - 2025 (USD Million)
FIG. 33 Germany antibody-drug conjugates market, 2014 - 2025 (USD Million)
FIG. 34 Asia Pacific antibody-drug conjugates market, 2014 - 2025 (USD Million)
FIG. 35 Japan antibody-drug conjugates market, 2014 - 2025 (USD Million)
FIG. 36 China antibody-drug conjugates market, 2014 - 2025 (USD Million)
FIG. 37 Latin America antibody-drug conjugates market, 2014 - 2025 (USD Million)
FIG. 38 Brazil antibody-drug conjugates market, 2014 - 2025 (USD Million)
FIG. 39 MEA antibody-drug conjugates market, 2014 - 2025 (USD Million)
FIG. 40 South Africa antibody-drug conjugates market, 2014 - 2025 (USD Million)
FIG. 41 Strategy framework
FIG. 42 Participant categorization